tiprankstipranks
Trending News
More News >
Microba Life Sciences Limited (AU:MAP)
:MAP
Australian Market

Microba Life Sciences Limited (MAP) AI Stock Analysis

Compare
1 Followers

Top Page

AU

Microba Life Sciences Limited

(Sydney:MAP)

Rating:39Underperform
Price Target:
AU$0.00
▼(-100.00%Downside)
Microba Life Sciences faces significant financial challenges, with persistent losses and negative cash flows being major concerns. Technical indicators suggest bearish trends, and valuation remains unattractive due to a negative P/E ratio. While revenue growth is a positive, the company's financial health and stock momentum present notable risks.

Microba Life Sciences Limited (MAP) vs. iShares MSCI Australia ETF (EWA)

Microba Life Sciences Limited Business Overview & Revenue Model

Company DescriptionMicroba Life Sciences Limited (MAP) is a biotechnology company specializing in microbiome analysis and related health solutions. The company operates within the healthcare and biotechnology sectors, providing advanced microbiome testing services and insights to support health professionals and researchers in understanding the role of the microbiome in health and disease. Microba's core products and services include comprehensive microbiome analysis and personalized health recommendations based on cutting-edge scientific research and technology.
How the Company Makes MoneyMicroba Life Sciences Limited generates revenue primarily through the provision of microbiome testing services. The company's key revenue streams include selling microbiome analysis kits to consumers and healthcare providers, offering subscription-based services for ongoing microbiome monitoring, and providing data-driven health insights and reports. Additionally, Microba collaborates with research institutions and pharmaceutical companies, offering research and development services, which contribute to its earnings. Strategic partnerships with healthcare providers and research organizations further enhance the company's revenue potential by expanding its market reach and integrating its solutions into broader health management systems.

Microba Life Sciences Limited Financial Statement Overview

Summary
Microba Life Sciences shows strong revenue growth but struggles with profitability and cash flow. Persistent negative margins and net losses highlight significant challenges. The balance sheet's strong equity and cash reserves support liquidity, but the ongoing cash burn poses a threat to long-term sustainability.
Income Statement
35
Negative
Microba Life Sciences has exhibited significant revenue growth over the years, with a notable increase from 5.4 million in 2023 to 12.1 million in 2024. However, persistent negative gross margins and net losses indicate profitability challenges. The EBIT and EBITDA margins have also been negative, reflecting ongoing operational losses. The company needs to address its cost structure to improve margins and profitability.
Balance Sheet
42
Neutral
The company's balance sheet shows a strong equity position with a low debt-to-equity ratio of 0.038. The equity ratio is also healthy at 71%, indicating asset financing primarily through equity. However, the persistent net losses have impacted return on equity, which remains negative. The company maintains significant cash reserves, supporting its liquidity position.
Cash Flow
28
Negative
Microba Life Sciences has been experiencing negative free cash flow, which has worsened from -15.4 million in 2023 to -19.9 million in 2024. The operating cash flow to net income ratio is unfavorable, highlighting cash burn from operations. Despite negative cash flows, financing activities have been a source of cash inflow, but reliance on external financing could pose future risks.
BreakdownTTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue16.90M12.09M5.42M4.69M3.73M2.91M
Gross Profit-349.08K5.91M-6.77M2.37M-5.30M-4.05M
EBITDA-16.14M-17.10M-17.07M-9.86M-6.28M-5.53M
Net Income-14.19M-19.94M-12.68M-11.47M-7.52M-6.65M
Balance Sheet
Total Assets50.79M58.04M46.95M39.48M18.49M10.81M
Cash, Cash Equivalents and Short-Term Investments17.45M20.89M32.04M30.58M13.03M6.90M
Total Debt3.47M1.58M1.14M1.33M269.02K563.65K
Total Liabilities15.10M16.82M8.23M5.94M3.46M3.10M
Stockholders Equity35.69M41.22M38.57M33.54M14.94M7.70M
Cash Flow
Free Cash Flow-9.50M-19.95M-15.43M-12.32M-7.85M-5.18M
Operating Cash Flow-6.66M-15.57M-12.39M-10.45M-7.18M-4.32M
Investing Cash Flow-3.99M-13.95M-3.00M-1.73M-522.48K-856.17K
Financing Cash Flow201.17K18.39M16.68M29.22M13.84M1.08M

Microba Life Sciences Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.08
Price Trends
50DMA
0.14
Negative
100DMA
0.17
Negative
200DMA
0.19
Negative
Market Momentum
MACD
-0.02
Positive
RSI
27.70
Positive
STOCH
-7.28
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:MAP, the sentiment is Negative. The current price of 0.08 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.14, and below the 200-day MA of 0.19, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 27.70 is Positive, neither overbought nor oversold. The STOCH value of -7.28 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:MAP.

Microba Life Sciences Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AUCTE
66
Neutral
AU$36.36M19.8787.09%2.68%1.86%16.10%
52
Neutral
$7.50B0.31-61.87%2.27%17.10%1.59%
AULDX
45
Neutral
AU$20.21M-51.49%80.84%57.59%
AUGSS
45
Neutral
AU$82.91M-47.52%44.61%16.40%
AUIIQ
45
Neutral
AU$41.30M-39.07%26.07%0.85%
AUBDX
40
Neutral
AU$24.15M-104.23%-17.26%
AUMAP
39
Underperform
AU$43.78M-33.42%158.37%36.73%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:MAP
Microba Life Sciences Limited
0.08
-0.10
-55.56%
AU:BDX
BCAL Diagnostics Limited
0.07
-0.07
-50.00%
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.03
-0.01
-25.00%
AU:CTE
Cryosite Limited
0.74
-0.36
-32.73%
AU:GSS
Genetic Signatures Ltd.
0.36
-0.34
-48.57%
AU:IIQ
Inoviq Ltd
0.37
-0.20
-35.09%

Microba Life Sciences Limited Corporate Events

Mercer Investments Ceases Substantial Holding in Microba Life Sciences
Jul 2, 2025

Mercer Investments (Australia) Limited, as the responsible entity of the Mercer Australian Small Companies Fund, has ceased to be a substantial holder in Microba Life Sciences Limited as of June 27, 2025. This change follows an increase in the total shares on issue by 67,177,796 shares, impacting the fund’s voting interests in the company.

The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.26 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.

Microba Life Sciences Initiates $14.5 Million Capital Raise
Jun 27, 2025

Microba Life Sciences Limited has announced a capital raise through a placement and a share purchase plan, aiming to gather a total of $14.5 million before costs. This financial maneuver involves issuing new ordinary shares and options, with the first tranche of shares already issued and quoted on the ASX. This capital raise is expected to bolster Microba’s financial position, potentially enhancing its market presence and operational capabilities.

The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.

Microba Life Sciences Launches $2 Million Securities Purchase Plan
Jun 27, 2025

Microba Life Sciences Limited has announced a Securities Purchase Plan (SPP) offering eligible shareholders the opportunity to subscribe for new shares and options. The SPP aims to raise up to $2 million and is fully underwritten by Morgans Corporate Limited and Canaccord Genuity (Australia) Limited. The issuance of new shares and options is contingent upon shareholder approval at a general meeting scheduled for August 8, 2025. This move is part of Microba’s strategy to strengthen its financial position and expand its market presence.

The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.

Microba Life Sciences Announces Quotation of New Securities on ASX
Jun 27, 2025

Microba Life Sciences Limited has announced the quotation of 67,177,796 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code MAP. This move is part of previously announced transactions and is expected to enhance the company’s market presence and liquidity, potentially benefiting stakeholders by increasing the accessibility of its shares.

The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.

Microba Life Sciences Resumes Trading Post-Capital Raise Announcement
Jun 23, 2025

Microba Life Sciences Limited, listed on the ASX under the ticker MAP, has announced the lifting of its trading suspension following a capital raising announcement. This development is expected to have a positive impact on the company’s operations, potentially enhancing its market positioning and offering new opportunities for stakeholders.

The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.

Microba Life Sciences Announces Securities Purchase Plan
Jun 23, 2025

Microba Life Sciences Limited has announced a proposed issue of securities under a securities purchase plan, with the offer set to close on August 6, 2025, and the issue date on August 13, 2025. This move is part of the company’s strategic efforts to raise capital, potentially impacting its market positioning and providing opportunities for stakeholders to invest in its future growth.

The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.

Microba Life Sciences Announces Proposed Securities Issue
Jun 23, 2025

Microba Life Sciences Limited has announced a proposed issue of securities, specifically options expiring on January 13, 2027, with a total of 46,222,222 securities to be issued. This strategic move is expected to bolster the company’s financial position and potentially enhance its market presence, offering stakeholders a glimpse into the company’s growth plans.

The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.

Microba Life Sciences Announces Proposed Securities Issue
Jun 23, 2025

Microba Life Sciences Limited announced a proposed issue of securities, including options expiring in August 2027 and ordinary fully paid shares. This move is part of the company’s strategy to raise capital, potentially enhancing its market position and operational capabilities in the life sciences sector.

The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.

Microba Life Sciences Announces New Securities Issue
Jun 23, 2025

Microba Life Sciences Limited has announced a proposed issue of 67,177,796 fully paid ordinary securities, with the issuance date set for June 27, 2025. This move is part of a strategic effort to enhance its capital structure, potentially impacting its market position and offering new opportunities for stakeholders.

The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.

Microba Life Sciences Secures $14.5M for Microbiome Testing Expansion
Jun 23, 2025

Microba Life Sciences Limited has successfully raised $14.5 million through a two-tranche placement and a share purchase plan to expand the clinical adoption of its microbiome testing products. The funding, supported by major shareholder Sonic Healthcare Limited, will be used to enhance product development, sales, and marketing efforts in Australia and the UK. Additionally, Microba has signed an exclusive agreement with The Doctors Laboratory in the UK, which is expected to strengthen its market presence and drive growth. The company aims to achieve regional break-even points by the end of FY26 and is on a strategic path to reach group breakeven within three years.

The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.

Microba Life Sciences Suspends Trading Ahead of Capital Raise Announcement
Jun 23, 2025

Microba Life Sciences Limited has requested a voluntary suspension of its securities from the ASX as it prepares to announce a capital raise. The suspension, effective from June 23, 2025, is expected to last until the company is ready to release details of the capital raise, anticipated by June 24, 2025. This move is part of Microba’s strategic efforts to secure funding for its ongoing projects in microbiome diagnostics and therapeutics, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.

Microba Life Sciences Initiates Trading Halt for Capital Raise
Jun 19, 2025

Microba Life Sciences Limited has requested a trading halt on its shares pending an announcement regarding a proposed capital raise. This strategic move is intended to facilitate the capital raise process, which could have significant implications for the company’s financial strategy and market operations.

The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.

Microba’s MetaPanel™ Test Achieves Breakthrough in Gastrointestinal Diagnostics
May 21, 2025

Microba Life Sciences Limited announced breakthrough results from their MetaPanel™ Pathogen Study, highlighting the test’s ability to identify clinically significant pathogens in patients with chronic gastrointestinal symptoms. The study found that 20% of patients tested positive for pathogens, with 78.4% of these pathogens often missed by routine tests. Notably, 100% of patients treated based on MetaPanel results experienced complete symptom resolution, underscoring the test’s potential to transform gastrointestinal diagnostics and treatment. This advancement positions Microba as a leader in precision gastroenterology, offering a novel pathway for diagnosing and treating chronic GI conditions.

The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.

Microba’s MetaXplore™ Test Shows Promising Results in GI Disorder Management
May 13, 2025

Microba Life Sciences Limited has announced preliminary results from a study involving over 4,600 patients using its MetaXplore™ GI Plus test. The study found that 71.4% of the reports identified actionable results, with a significant portion showing abnormal microbiome markers linked to gastrointestinal health. The findings suggest that the MetaXplore test can significantly aid clinicians in diagnosing and managing chronic lower gastrointestinal disorders. Additionally, a separate survey indicated that 65.5% of patients reported health improvements after following clinician-directed recommendations based on the test results. This highlights the potential of MetaXplore to reshape clinical management and improve outcomes for patients with these conditions, addressing an estimated addressable market of over 82 million patients across several countries.

The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.

Microba Life Sciences Announces Cessation of Securities
May 12, 2025

Microba Life Sciences Limited announced the cessation of 1,200,000 securities due to the expiry of options without exercise or conversion as of April 29, 2025. This development may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies and market positioning.

Microba Life Sciences Releases Q3 FY25 Investor Presentation
Apr 30, 2025

Microba Life Sciences Limited has released its Q3 FY25 Investor Presentation and Webinar, presented by CEO Dr. Luke Reid. The presentation is available on demand via Microba’s Investor Hub, and stakeholders are encouraged to engage by submitting questions through the platform. This initiative reflects Microba’s commitment to transparency and stakeholder engagement, potentially enhancing its industry positioning by fostering investor confidence.

Microba Life Sciences Reports Strong Q3 Growth and Advances in IBD Care
Apr 30, 2025

Microba Life Sciences Limited reported significant growth in its testing products for Q3 FY25, with MetaXplore and MetaPanel showing strong sales in Australia and the UK. The company’s strategic focus on core diagnostic products is reflected in its financial performance, with expected revenue growth and a transition to a partnering-focused phase for its therapeutics business. The successful clinical studies on MetaPanel for Inflammatory Bowel Disease (IBD) highlight its potential to transform patient care by detecting pathogens missed by routine testing, supporting its integration into standard care protocols.

Microba Life Sciences to Release Q3 FY25 Report and Host Investor Presentation
Apr 28, 2025

Microba Life Sciences Limited announced the release of its Q3 FY25 Quarterly Activities Report and Investor Presentation, scheduled for April 30, 2025. The company will also provide a video presentation by CEO Dr. Luke Reid, accessible through its Investor Hub, allowing stakeholders to engage and submit questions. This initiative underscores Microba’s commitment to transparency and stakeholder engagement, potentially enhancing its market position and investor relations.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 24, 2025